All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BioMarin Pharmaceutical Inc., of Novato, Calif., said updated data from its Phase I/II extension study of GALNS (N-acetylgalactosamine 6-sulfatase), showed no new or consistent patterns of clinically meaningful or treatment-limiting adverse events in patients with mucopolysaccharidosis Type IVA.